New Delhi, December 28, 2022: We are very excited to announce that Anuva and Max Healthcare, one of the largest healthcare services companies in India, have entered into a partnership to conduct genomic-based research on various communicable and non-communicable diseases in India.

Max Healthcare signs MOU with Anuva for genomic-based research on various diseases in India

  • Aims to identify relevant insights for precision medicine application
  • To facilitate knowledge sharing among scientists, epidemiologists and other stakeholders

Max Healthcare, one of the largest healthcare services company in India, and Anuva, a genomics biotech company, today announced that they have entered into a Memorandum of Understanding (MoU) to conduct genomic-based research on various communicable and non-communicable diseases in India.

The objective of the research will be to identify insights for precision medicine application across diseases including breast cancer, lung cancer, diabetes, cardiac disease, kidney disease, drug resistant tuberculosis, and others.

As part of the five-year engagement, Max Healthcare will provide its expertise in clinical research and will serve as the clinical center for data and/or sample collection from individuals who consent to share their data for the purpose of research.

Anuva’s expertise in genomics for diverse population groups uniquely positions them to create insights and discoveries that are directly relevant to the Indian population. Anuva is a translational research company that is creating the most diverse Genomic Bio & Data Bank of Asian Populations.

On signing of the MoU, Dr. Sandeep Budhiraja, Group Medical Director from Max Healthcare said: “There is a lot to discover in the field of genetic and lifestyle diseases. With the coming of precision medicine and genomics, it has the potential to provide efficient solutions and transform the way we look at modern medicine today. It gives us an immense pleasure to collaborate with Anuva biotech, which has been making significant strides into various areas of cutting-edge research, aiming to solve important scientific problems.”

Dr. Jonathan Picker, Chief Executive Officer from Anuva, said: “The promise and potential of genomics to transform medicine is enormous. The opportunity to work with Max Healthcare is extremely important, as they bring great expertise in diagnostics, treatment and clinical research across the disease spectrum. Together, we can help to make personalised precision care a reality and we are tremendously excited to collaborate with Max Healthcare.”

Apart from research, the institutions will also explore the possibility of conducting joint training, fellowships, exchange visits, knowledge and technology transfer for cross-learning and capacity building in the fields of biomedical science and arenas of public health.

The partnership will also facilitate knowledge sharing and communication among scientists, epidemiologists and other stakeholders having mutual interest in the discipline.

The MoU was signed by Mr. Rohit Pandit, Secretary Max Society of Academics Innovation and Research at Max Healthcare and Dr. Jonathan Picker, CEO of Anuva.

About Max Healthcare:

Max Healthcare Institute Limited (MHIL) is one of India’s largest hospital chain operators (considering only income from healthcare services) in fiscal 2023. It is committed to the highest standards of medical and service excellence, patient care, scientific and medical education.

MHIL has major concentration in North India consisting of a network of 17 healthcare facilities. Out of the total network, eight hospitals and four medical centres are located in Delhi and the NCR and the others are located in the cities of Mumbai, Mohali, Bathinda and Dehradun. The Max network includes all the hospitals and medical centres owned and operated by the company and its subsidiaries, partner healthcare facilities and managed healthcare facilities. These include state-of-the-art tertiary and quaternary care hospitals at Saket, Patparganj, Vaishali, Rajendra Place and Shalimar Bagh in Delhi NCR and one each in Mumbai, Mohali, Bathinda and Dehradun, secondary care hospital in Gurgaon and Day Care Centres at Noida, Lajpat Nagar and Panchsheel Park in Delhi NCR and one in Mohali, Punjab. The hospitals in Mohali and Bathinda are under PPP arrangement with the Government of Punjab.

In addition to its core hospital business, MHIL has two SBUs – Max@Home and MaxLab. Max@Home is a platform that provides health and wellness services at home and Max Lab offers diagnostic services to patients outside its network.

Read about it on Economic Times here

Dr. Jonathan Picker Chief Executive Office

Dr. Jonathan Picker is an affiliate faculty member and clinical geneticist at Boston's Children's Hospital, Harvard Medical School.

With 25 years of experience in Pediatrics and Genetics, Dr. Picker specializes in the interface of clinical care and applied genetic and genomic research. Dr. Picker's research spans diagnostic tools in genetics to descriptive analysis of rare disorders to molecular neuroscience. He was the co-founder and Director of the first Pediatric Pharmacogenomic clinic in the USA; as well as Director of the Harvard Medical School Advanced Human Genetics Training Program Course.

Dr. Picker is the recipient of various prestigious awards, including the first Sidney R. Baer Jr. Prize for Mental health Research. He has authored numerous research papers involving informative cases, molecular biology, behavioral neuroscience, applied clinical genetic guidelines as well as invited reviews and chapters.

Dr. Picker holds a bachelor's degree of Medical Biology in Genetics, and an MBChB in Medicine from Aberdeen University, UK. He also holds an MS in Genetics and Biochemistry and a PhD in Molecular Biology from Newcastle University, UK.

Kushagra SharmaPresident & Board Member

Kushagra Sharma is a seasoned business leader with a career spanning entrepreneurship as well as general management, Kushagra has deep expertise in developing and executing business plans in start-ups as well as large corporations. He is responsible for the revenue growth of the business, strategic planning, and partnerships at Anuva.

Before joining Anuva, he was responsible for the strategy and project execution in launching 4G digital services for Reliance Jio in India. Kushagra has previously served in leadership roles in companies like British Telecom, MTS Sistema Shyam, Grail Research and Evalueserve.

He holds a bachelor's degree from Indian Institute of Technology, Delhi and an MBA from INSEAD, Fontainebleau.

Dr. Asmi ShahVice President of Data and Technology

Dr. Asmi Shah brings in her data science expertise in dealing with big data, managing and standardizing multidisciplinary large scale biological datasets in the field of drug discovery through genomics and phenomics. She is responsible for the research and development of end to end software products and workflows.

Before joining Anuva, she contributed to the research of drug discovery done with the use of high content/throughput screening on various zebrafish assays at University of Heidelberg in Germany and at Harvard Medical School, USA. She has also taken up various technical roles in product management and software R&D with different corporate industries such as Intel, Rambus and Inform Technologies in the USA and with data analytics startups in India.

Dr. Shah holds a bachelor’s degree from Saurashtra University, India, an MS from San Jose State University, USA and has pursued her PhD from University of Heidelberg, Germany under a Marie Curie fellowship.

Abhishek Kumar Chairman & Executive Director

Abhishek Kumar brings in extensive experience of acquiring, merging, carving out and repositioning companies globally. He founded Joulon - a KKR company, and has led large scale distributed businesses globally.

He holds a bachelor’s degree from Indian Institute of Technology, Kanpur and an MBA from Harvard Business School.